118 results
6-K
TAK
Takeda Pharmaceutical Co
27 May 20
Current report (foreign)
6:12am
we established a Global Crisis Management Committee to leverage our deep expertise in executing a pandemic response strategy and health and safety … to climate change. Meeting them requires a long-term, sustainable business model and strategy. Our strategy is sound and well executed, and will allow us
6-K
TAK
Takeda Pharmaceutical Co
26 Feb 21
Current report (foreign)
6:01am
to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
–Asset transfer furthers Takeda’s global strategy to focus on five key business areas … -Derived Therapies, Oncology, and Neuroscience – core to its global long-term growth strategy.
“Today’s transaction enables us to sharpen our focus
6-K
TAK
Takeda Pharmaceutical Co
14 Nov 19
Current report (foreign)
6:14am
:30 p.m. EST in New York City to outline how its science-first, patient-centric strategy, diverse portfolio of approved medicines and its R&D engine … presentations and speakers:
Welcome and Opening Remarks, Sheelagh Cawley-Knopf, Head, R&D Global Portfolio Strategy
Takeda: A Global Values-Based, R&D
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
6 Apr 21
Current report (foreign)
6:29am
Claus Jepsen, Head of Global Product and Launch Strategy, Rare Genetic and Hematology 08:35 – 08:40 21:35 – 21:40 Break 08:40 – 09:35 21:40 – 22:35 … Neuroscience Strategy, Soticlestat & Orexin Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit Elena Koundourakis, Head of Orexin Franchise
6-K
TAK
Takeda Pharmaceutical Co
11 Jan 22
Current report (foreign)
6:04am
Number
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
SIGNATURES … Accounting Officer and Corporate Controller
News Release
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the
40th Annual
DRS/A
EX-1.2
4wl59xj4j362v7s36
16 Nov 18
Draft registration statement (amended)
12:00am
20FR12B
EX-1.2
k9h0i2ukefr
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
6-K
EX-99.1
khh2lxzp6c
21 Jun 21
Current report (foreign)
6:05am
20FR12B/A
EX-1.2
6kurfq e792s
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
6-K
EX-99.2
r8ik18c
21 Nov 19
Current report (foreign)
6:08am
6-K
EX-99.1
773avfco
30 May 23
Current report (foreign)
6:19am
6-K
tyrrbmt4zzjfxfyzk
24 Aug 20
from 6-K
6:04am
6-K
EX-99.1
hfvowmc
14 Dec 23
Current report (foreign)
6:01am
6-K
EX-99.1
72o7j8lsa505ui26
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
1e50 tyqd0hyl8
17 Dec 20
Current report (foreign)
6:01am
6-K
EX-99.1
q048tvhi0fxcj
31 May 22
Current report (foreign)
6:14am
6-K
EX-99.1
gvkn8z4v
28 May 21
Current report (foreign)
6:07am
6-K
enlnxr3
14 Jan 20
Current report (foreign)
6:56am
6-K
EX-99.1
feu77icqd87drhyherd
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
6-K
EX-99.1
o1qzj3b1dl18m2xk0
15 Nov 19
Current report (foreign)
6:24am